Comprehend Systems, Inc., the makers of Comprehend Clinical, will be offering live demonstrations of the new version of their software at the Drug Information Association's 47th Annual Meeting, DIA 2011, to be held in Chicago on June 19-23, 2011. Comprehend Clinical is a next-generation web-based reporting and visualization platform which makes it easier to understand, explore, and analyze clinical data by allowing end-users to access multiple data sources simultaneously.
"It is a hybrid ETL and reporting and visualization tool that leverages the power of existing CDMS, EDC, and other clinical data systems," said Rick Morrison, CEO and Co-founder of Comprehend Systems, Inc. Live demonstrations in Booth 502 at DIA 2011 will showcase how Comprehend Clinical can facilitate real-time decision making for data managers, clinicians, clinical monitors, and executives.
Listen to Rick Morrison discuss analytics in clinicaltrials further here.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.